Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Gross Margin (2016 - 2025)

IGC Pharma has reported Gross Margin over the past 16 years, most recently at 51.83% for Q3 2025.

  • Quarterly Gross Margin rose 377.0% to 51.83% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 46.2% through Sep 2025, down 1001.0% year-over-year, with the annual reading at 48.7% for FY2025, 580.0% down from the prior year.
  • Gross Margin was 51.83% for Q3 2025 at IGC Pharma, up from 46.95% in the prior quarter.
  • Over five years, Gross Margin peaked at 67.86% in Q3 2021 and troughed at 30.72% in Q4 2022.
  • The 5-year median for Gross Margin is 48.06% (2024), against an average of 50.51%.
  • Year-over-year, Gross Margin skyrocketed 4706bps in 2021 and then crashed -2473bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 43.66% in 2021, then dropped by -30bps to 30.72% in 2022, then surged by 112bps to 65.2% in 2023, then tumbled by -38bps to 40.47% in 2024, then increased by 28bps to 51.83% in 2025.
  • Per Business Quant, the three most recent readings for IGC's Gross Margin are 51.83% (Q3 2025), 46.95% (Q2 2025), and 46.67% (Q1 2025).